GlassScriptPhysician profile
Richard J Cross
NPI 1972771061
$96,443.89
in general payments reported to CMS, 2019-2025
29 companies · $8,216 in 2025
The $8,216 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $19K · 2021: $21K · 2022: $783 · 2023: $3,734 · 2024: $22K · 2025: $8,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $2,730 · Honoraria: $2,275 · Travel and Lodging: $957 · Education: $55.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,162.50 |
| Food and Beverage | $2,730.47 |
| Honoraria | $2,275.00 |
| Travel and Lodging | $956.79 |
| Education | $55.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $53,876.99 | 2019-2025 | Lokelma |
| Lilly USA, LLC | $18,812.74 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,579.66 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $6,426.12 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $3,306.94 | 2022-2025 | Purified Cortrophin Gel |
| Covidien LP | $658.78 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $444.97 | 2021-2025 | Lutonix Drug Coated Balloon, Wavelinq, Set Aspirex S 10f 110cm |
| Bayer Healthcare Pharmaceuticals INC. | $361.19 | 2021-2024 | |
| Vifor Pharma, INC. | $264.94 | 2019-2020 | |
| Ardelyx, INC. | $250.10 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $243.87 | 2019-2024 | Tavneos |
| Calliditas Therapeutics US INC. | $145.90 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $145.23 | 2020-2023 | Jynarque |
| Mallinckrodt Enterprises LLC | $121.83 | 2019 | |
| Recor Medical INC | $121.41 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $121.36 | 2022 | |
| Mozarc Medical US LLC | $101.98 | 2024 | Chameleon |
| Novartis Pharmaceuticals Corporation | $71.97 | 2024-2025 | |
| Horizon Therapeutics Plc | $59.78 | 2023 | Krystexxa |
| Cormedix INC. | $54.14 | 2024-2025 | Defencath, Defencath |
| Travere Therapeutics, INC. | $48.88 | 2021-2025 | Thiola |
| Daiichi Sankyo INC. | $37.78 | 2019-2022 | |
| Avenu Medical INC. | $36.64 | 2020 | |
| Medtronic, INC. | $35.10 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.70 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $24.53 | 2022 | |
| Aurinia Pharma U.S., INC. | $23.97 | 2022 | |
| Angiodynamics, INC. | $18.59 | 2022 | |
| Akebia Therapeutics INC | $17.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.